Maa: Kanada
Kieli: englanti
Lähde: Health Canada
PROCHLORPERAZINE (PROCHLORPERAZINE MALEATE)
AA PHARMA INC
N05AB04
PROCHLORPERAZINE
10MG
TABLET
PROCHLORPERAZINE (PROCHLORPERAZINE MALEATE) 10MG
ORAL
100
Prescription
PHENOTHIAZINES
Active ingredient group (AIG) number: 0106181001; AHFS:
APPROVED
2000-02-03
PRESCRIBING INFORMATION PR PROCHLORAZINE PROCHLORPERAZINE MALEATE TABLETS USP 5 MG AND 10 MG PROCHLORPERAZINE/TABLET ANTIPSYCHOTIC/ANTIEMETIC AA PHARMA INC. DATE OF REVISION: 1165 CREDITSTONE ROAD, UNIT #1 August 31, 2012 VAUGHAN, ONTARIO L4K 4N7 CONTROL NUMBER: 158279 1 PRESCRIBING INFORMATION PROCHLORAZINE Prochlorperazine Tablets USP 5 mg and 10 mg THERAPEUTIC CLASSIFICATION Antipsychotic/Antiemetic ACTIONS AND CLINICAL PHARMACOLOGY Prochlorperazine is a piperazine phenothiazine derivative with antipsychotic, antiemetic and weak sedative activity. Prochlorperazine has actions similar to those of other phenothiazine derivatives but appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extrapyramidal reactions. Prochlorperazine is well absorbed from the gastrointestinal tract. Onset of action following oral administration is 30 to 40 minutes; 60 minutes for suppositories and 10 to 20 minutes after i.m. administration. Duration of action for all routes is 3 to 4 hours. Prochlorperazine distributes to most body tissues with high concentrations being distributed into liver and spleen. Prochlorperazine enters the enterohepatic circulation and is excreted chiefly in the feces. 2 INDICATIONS AND CLINICAL USE In the management of manifestations of psychotic disorders such as agitation, confusion, delusion, tension and anxiety. It is also effective in controlling nausea and vomiting due to stimulation of the chemoreceptor trigger zone. In selected patients, prochlorperazine may be of value for the relief of excessive anxiety, accompanied by severe tension and agitation, associated with psychoneurotic or somatic conditions. CONTRAINDICATIONS Should not be administered in the presence of circulatory collapse, altered states of consciousness or comatose states, particularly when these are due to intoxication with central depressant drugs (alcohol, hypnotics, narcotics). It is contraindicated Lue koko asiakirja